In ₹ Crore except Per Share Latest Annual | NGLFINE FY26 | SYNCOMF FY26 | JAGSNPHARM FY26 | HESTERBIO FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | 34.67× | ◆ 23.74× | 36.54× | 33.59× | 33.59× +3% | |
| P/B | 5.07× | ◆ 4.36× | 5.67× | 5.25× | 5.25× -3% | |
| EV/EBITDA | 23.87× | ◆ 21.92× | 26.79× | 24.42× | 24.42× -2% | |
| Market Cap | ₹1,669 Cr | ₹1,808 Cr | ₹1,566 Cr | ₹1,931 Cr | ₹1,808 Cr -8% | |
| Growth | ||||||
| Revenue CAGR 3Y | 21.68% | ◆ 29.69% | 6.66% | 7.72% | 7.72% +181% | |
| Revenue CAGR 5Y | — | — | 8.85% | ◆ 9.19% | 9.02% | |
| Net Income CAGR 3Y | 32.91% | ◆ 56.16% | 17.26% | 27.04% | 27.04% +22% | |
| Revenue YoY (latest Q) | ◆ 33.57% | 7.38% | 8.76% | -8.16% | 7.38% +355% | |
| Net Income YoY (latest Q) | 99.09% | 57.71% | 22.18% | ◆ 459.27% | 57.71% +72% | |
| Profitability | ||||||
| EBITDA Margin | 14.51% | 15.83% | 20.22% | ◆ 26.05% | 20.22% -28% | |
| Net Income Margin | 9.61% | 15.63% | 15.00% | ◆ 17.28% | 15.63% -39% | |
| Return on Common Equity | 14.62% | ◆ 18.42% | 15.60% | 15.13% | 15.60% -6% | |
| Return on Capital Employed | 13.43% | 16.48% | ◆ 16.86% | 12.90% | 16.48% -19% | |
| Return on Assets | 8.82% | ◆ 14.32% | 13.60% | 8.48% | 13.60% -35% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.33× | ◆ 0.00× | 0.00× | 0.51× | 0.00× | |
| Interest Coverage | 11.89× | ◆ 61.38× | 47.31× | 6.20× | 47.31× -75% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹501 Cr | ₹489 Cr | ₹287 Cr | ₹333 Cr | ₹333 Cr +51% | |
| Net Income | ₹48.1 Cr | ₹76.4 Cr | ₹43.1 Cr | ₹57.5 Cr | ₹57.5 Cr -16% | |
| Total Assets | ₹545 Cr | ₹534 Cr | ₹317 Cr | ₹678 Cr | ₹534 Cr +2% | |
| EPS | ₹77.9 | ₹0.81 | ₹6.4 | ₹67.57 | ₹6.4 +1117% | |
| Book Value per Share | ₹532.91 | ₹4.41 | ₹41.24 | ₹432.34 | ₹41.24 +1192% | |